Advertisement

ADVERTISEMENT

Stephanie Holland

Conference Coverage
Tumor Treating Fields Combined With Radiotherapy is Well Tolerated in Newly Diagnosed Glioblastoma
06/15/2023
The addition of tumor treating fields to radiotherapy is well tolerated in adult patients with newly diagnosed glioblastoma, according to findings from the phase 1/2 PriCoTTF study.
The addition of tumor treating fields to radiotherapy is well tolerated in adult patients with newly diagnosed glioblastoma, according to findings from the phase 1/2 PriCoTTF study.
The addition of tumor treating...
06/15/2023
Oncology
News
Repotrectinib Demonstrated Durable Clinical Activity Among Patients With ROS1 Fusion-Positive Non-Small Cell Lung Cancer
01/24/2024
Results from a phase 1/2 registrational study demonstrated that repotrectinib demonstrated durable clinical activity among patients with ROS1 fusion-positive non-small cell lung cancer, regardless of previous treatment with a ROS1 TKI.
Results from a phase 1/2 registrational study demonstrated that repotrectinib demonstrated durable clinical activity among patients with ROS1 fusion-positive non-small cell lung cancer, regardless of previous treatment with a ROS1 TKI.
Results from a phase 1/2...
01/24/2024
Oncology
News
Molecular Classification Predicts Radiotherapy Benefit in Early-Stage Endometrioid Endometrial Cancer
08/29/2023
According to an analysis of data from the PORTEC-1 and PORTEC-2 trials, molecular classification can predict response to radiotherapy in early-stage endometrioid endometrial cancer.
According to an analysis of data from the PORTEC-1 and PORTEC-2 trials, molecular classification can predict response to radiotherapy in early-stage endometrioid endometrial cancer.
According to an analysis of data...
08/29/2023
Oncology
News
Patritumab Deruxtecan for Patients With Previously Treated, EGFR-Mutated Non-Small Cell Lung Cancer
10/18/2023
Results from the phase 2 HERTHENA-Lung01 trial found that patritumab deruxtecan is clinically durable and effective for patients with previously treated EGFR-mutated NSCLC.
Results from the phase 2 HERTHENA-Lung01 trial found that patritumab deruxtecan is clinically durable and effective for patients with previously treated EGFR-mutated NSCLC.
Results from the phase 2...
10/18/2023
Oncology
News
Benefit From Adjuvant Abemaciclib Plus Endocrine Therapy Sustained Among Patients With HR-Positive, HER2-Negative Breast Cancer
02/22/2024
Updated 5-year efficacy results from the phase 3 monarchE trial demonstrated that adjuvant abemaciclib plus endocrine therapy continued to reduce the risk of invasive and distant disease recurrence beyond completion of treatment among...
Updated 5-year efficacy results from the phase 3 monarchE trial demonstrated that adjuvant abemaciclib plus endocrine therapy continued to reduce the risk of invasive and distant disease recurrence beyond completion of treatment among...
Updated 5-year efficacy results...
02/22/2024
Oncology
News
Addition of Berzosertib to Topotecan Did Not Improve PFS Among Patients With Relapsed Small Cell Lung Cancer
11/13/2023
According to results from a phase 2 study, the addition of berzosertib to topotecan significantly improved overall survival but did not improve progression-free survival among patients with relapsed small cell lung cancer.
According to results from a phase 2 study, the addition of berzosertib to topotecan significantly improved overall survival but did not improve progression-free survival among patients with relapsed small cell lung cancer.
According to results from a...
11/13/2023
Oncology
News
Prophylactic Cranial Irradiation Improved Survival Outcomes Compared to Consolidative Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer
09/21/2023
Results of a comparison study demonstrated PCI was associated with greater overall survival and progression-free survival improvement compared to consolidative TRT among patients with extensive-stage small cell lung cancer previously treated...
Results of a comparison study demonstrated PCI was associated with greater overall survival and progression-free survival improvement compared to consolidative TRT among patients with extensive-stage small cell lung cancer previously treated...
Results of a comparison study...
09/21/2023
Oncology
Conference Coverage
Addition of Zanidatamab to Standard Palbociclib Plus Fulvestrant Improved Survival, Response in HER2-Positive, HR-Positive, Metastatic Breast Cancer
12/08/2023
According to primary results from a phase 2a study, the addition of zanidatamab to standard palbociclib and fulvestrant demonstrated promising progression-free survival and durable response among patients with HER2-positive, hormone...
According to primary results from a phase 2a study, the addition of zanidatamab to standard palbociclib and fulvestrant demonstrated promising progression-free survival and durable response among patients with HER2-positive, hormone...
According to primary results...
12/08/2023
Oncology
News
Adjuvant Atezolizumab After Chemotherapy May Extend OS Among Patients With PD-L1 High, Resected Stage II-IIIA NSCLC
08/02/2023
According to findings from the phase 3 IMPOWER010 trial, adjuvant atezolizumab following surgical resection and chemotherapy may extend overall survival compared to best supportive care among patients with PD-L1 high, stage II to IIIA NSCLC.
According to findings from the phase 3 IMPOWER010 trial, adjuvant atezolizumab following surgical resection and chemotherapy may extend overall survival compared to best supportive care among patients with PD-L1 high, stage II to IIIA NSCLC.
According to findings from the...
08/02/2023
Oncology
News
Efficacy, Safety of Sacituzumab Govitecan Among Patients With Heavily Pretreated, Relapsed/Refractory Metastatic or Locally Advanced Head and Neck Squamous Cell Carcinoma
10/21/2023
According to results from the phase 2 TROPiCS-03 study, sacituzumab govitecan demonstrated efficacy and tolerable safety among patients with heavily pretreated, relapsed or refractory, metastatic or locally advanced head and neck squamous...
According to results from the phase 2 TROPiCS-03 study, sacituzumab govitecan demonstrated efficacy and tolerable safety among patients with heavily pretreated, relapsed or refractory, metastatic or locally advanced head and neck squamous...
According to results from the...
10/21/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
December 9 ⁠–⁠ December 11
AIBD logo
December 9 ⁠–⁠ December 11
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
December 14 ⁠–⁠ December 15
February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use